Tezspire (Tezepelumab-Ekko) for Asthma

Overview
Tezspire is approved by the U.S. Food and Drug Administration (FDA) for the add-on maintenance treatment of severe asthma in adults and children aged 12 years and older. It is intended for individuals whose asthma is not well controlled with other treatments. Tezspire is not used for immediate relief of asthma symptoms like acute bronchospasms or status asthmaticus (a severe asthma episode requiring emergency care). Tezspire is also known by its drug name, tezepelumab-ekko.

Tezspire is a biologic medication that blocks thymic stromal lymphopoietin (TSLP), a protein involved in the inflammatory process of asthma. By inhibiting TSLP, Tezspire helps to reduce asthma exacerbations and improve lung function, though its exact mechanism of action in treating asthma is not completely understood.

How do I take it?
Prescribing information states that Tezspire is administered as a subcutaneous (under the skin) injection. The recommended dosing schedule is once every four weeks. Tezspire comes in single-dose vials, pre-filled syringes, or pre-filled pens, and it can be injected into the thigh, abdomen, or upper arm. The medication should be taken exactly as prescribed by a health care provider.

Side effects
Common side effects of Tezspire include pharyngitis (sore throat), arthralgia (joint pain), and back pain.

Rare but serious side effects may include hypersensitivity reactions (such as anaphylaxis, a severe allergic reaction), which can occur within hours or days of administration. Other potential risks include worsening asthma symptoms if corticosteroids are reduced too quickly, and parasitic infections (helminth infections) that may not respond well to treatment.

For more information about this treatment, visit:

Label: Tezspire — Tezepelumab-Ekko Injection, Solution — DailyMed